There have been many studies describing the effect of branchedchain amino acid (BCAA) on the protein metabolism. The continuous intravenous infusion of BCAA, particularly infusion of Leu, has been reported to have an anabolic effect on the protein metabolism by increasing protein synthesis [1] and decreasing protein breakdown [16, 20] . These results suggest that BCAA has an anabolic effect. Multiple BCAA oral supplementation before and during prolonged exercise (77 and 308 mg/kg body wt) showed similar effects on skeletal muscle preservation by suppressing the protein breakdown induced by exercise [17, 18] . These results suggest that BCAA supplementation during exercise can effectively suppress protein breakdown induced by exercise. However, the precise amount of BCAA needed to affect the muscle protein metabolism during exercise has yet to be elucidated.
Introduction
There have been many studies describing the effect of branchedchain amino acid (BCAA) on the protein metabolism. The continuous intravenous infusion of BCAA, particularly infusion of Leu, has been reported to have an anabolic effect on the protein metabolism by increasing protein synthesis [1] and decreasing protein breakdown [16, 20] . These results suggest that BCAA has an anabolic effect. Multiple BCAA oral supplementation before and during prolonged exercise (77 and 308 mg/kg body wt) showed similar effects on skeletal muscle preservation by suppressing the protein breakdown induced by exercise [17, 18] . These results suggest that BCAA supplementation during exercise can effectively suppress protein breakdown induced by exercise. However, the precise amount of BCAA needed to affect the muscle protein metabolism during exercise has yet to be elucidated.
Abstract
This study aimed at evaluating the effect of a single oral intake of branched-chain amino acids (BCAA) with Arg on skeletal muscle protein metabolism during moderate exercise in young individuals. Eight healthy volunteers (4 males and 4 females, means ± SEM, 26 ± 1 yrs, 177.8 ± 3.7 cm, 72.6 ± 3.9 kg) were studied in a randomized double-blind placebo-controlled cross-over trial. The subjects performed 3 bouts of 20-min cycling exercise (5-min break between each bout) at 126 ± 13 W corresponding to 50 % of the maximal work intensity. A single oral supplement of either a BCAA drink containing 2 g of BCAA and 0.5 g of Arg or an isocaloric placebo drink was given at 10 min of the 1st exercise bout. Both arterial and venous blood samples were simultaneously taken from the radial artery and the femoral vein, respectively. Blood flow in the femoral artery was determined using the ultrasound Doppler technique. The blood sampling and blood flow measurements were performed at rest, every 10 min during each exercise bout. Net balance of BCAA and Phe across the leg muscles were measured by the arteriovenous difference method. The BCAA ingestion resulted in increases in both the plasma BCAA concentration and BCAA uptake into the working leg. The Phe release from the leg during exercise significantly increased as compared to the basal level in the placebo trial (0.97 ± 0.28 vs. 0.23 ± 0.22 μmol/min, p < 0.05). In the BCAA trial, the cumulative Phe release from the leg during the 3rd exercise bout was significantly lower than that in the placebo trial (5.0 ± 7.4 vs. 35.9 ± 13.2 μmol/25 min, p < 0.05). These results suggest that endurance exercise at moderate intensity enhances proteolysis in working muscles, and a single oral intake of 2 g of BCAA with Arg at onset of exercise effectively suppresses exercise-induced skeletal muscle proteolysis.
We recently investigated the dose-response relationship of a single BCAA ingestion during rest in healthy subjects, and reported that a single ingestion of more than 2 g of BCAA increased the plasma BCAA concentration and then maintained it at a significantly higher level longer than 2 hours after the ingestion [8] . Therefore, a single ingestion of 2 g of BCAA is thus suggested to increase the circulatory BCAA level and BCAA supply to the muscle during endurance exercise.
Arg has been reported to be a potent stimulator of growth hormone (GH) and insulin [12] . Furthermore, Arg has also been reported to induce nitric oxide dependent vasodilation [3] and thereby increase the blood flow [22] . Therefore, the addition of Arg to the BCAA supplement is suggested to induce an additional anabolic effect on the protein metabolism.
This study was designed to investigate the effect of a single ingestion of 2 g of BCAA with Arg on the protein metabolism during 1 hour of exercise at a moderate intensity.
Materials and Methods

Subjects
Eight healthy untrained young subjects (four males and four females: means ± SEM, age 26 ± 1 yrs; height 177.8 ± 3.7 cm; body weight 72.6 ± 3.9 kg) were enrolled in this study. The study protocol was approved by the Scientific Ethical Committee for Ringkjøbing, Ribe and Sønderjylland Counties. All subjects were informed about possible risks and discomforts that might be involved in this study, and their written consent to participate was obtained. Prior to the experiments, the subjects underwent medical examinations, and an incremental cycling test to determine their maximal workload (251 ± 26 W).
Experimental design
This study was carried out as a randomized double-blind placebo-controlled cross-over trial. All 8 subjects participated in two trials, separated by at least 2 wk, in which skeletal muscle protein metabolism during moderate exercise was evaluated after the ingestion of 2 different test drinks (a BCAA drink or an isocaloric placebo drink). The BCAA drink contained 2 g of total BCAA (Val 0.5 g; Leu 1.0 g; Ile 0.5 g), 0.5 g of Arg, and 20 g of carbohydrates in 500 mL. The isocaloric placebo drink, which contained 2.5 g of dextrin instead of BCAA and Arg, closely corresponded to the isocaloric to BCAA drink. Both test drinks contained the same calories (377 kJ/500 mL). The taste and color of the two test drinks were indistinguishable. The test drinks were provided in a randomized order and double-blinded fashion.
Experimental Procedures
The experimental protocol is depicted in Fig. 1 . All subjects were instructed to maintain their normal diet and refrain from strenuous activities for 7 days before the trials. In addition, the subjects were instructed to record their food intake and physical activity on the day prior to the 1st exercise, and to repeat the same diet and same activity level in accordance with the record on the day prior to the 2nd exercise. On the exercise test day, the subjects were admitted to the hospital at 8:00 a.m. after an overnight fast (> 12 h) and then a standardized breakfast (2647 kJ; carbohydrate 66.5 g, protein 21.2 g, fat 31.3 g) was served. The subjects were instructed to rest until starting the cycling exercise. At 10:30 a.m. the subjects ingested a nonprotein containing energy supplement as an intra meal (419 kJ; carbohydrate 25 g, protein 0 g, fat 0 g). At 12:00 p.m. the radial artery and femoral vein were catheterized under local anesthesia (1 % xylocaine infiltration). The Seldinger technique was used to insert the catheters (20 gauge; Arrow International Inc., Reading, PA, USA). The inserting position of a catheter for the femoral vein was at an angle of 35 (30 -40) degrees formed by the lines of Trochanter major-Epicondylas and the inserting point, and 14 (12 -16) cm in the distal direction from the Trochanter major. The femoral vein catheter was advanced 14 (11.5 -16.5) cm in the proximal direction. The radial artery catheter was inserted ∼ 2 cm above the wrist and advanced ∼ 5 cm in a proximal direction. At 1:15 p.m. after at least 45 min of a basal period after the completion of catheterization, the subjects started to exercise for 60 min on the cycle ergometer (Strength Ergo ® 240, Mitsubishi Electric Engineering Co., Ltd., Tokyo, Japan). The subjects performed 3 sets of 20-min cy- Fig. 1 Experimental protocol. The study was conducted using a double-blind cross-over design with a 2-week washout period. After a 45-min rest following catheterization, the exercise test was conducted.
The exercise test consisted of 3 sets of 20-min exercise with a 5-min rest between each exercise bout. The subjects drank either a BCAA drink or a placebo drink at 10 min of the 1st exercise bout. The blood sampling and the blood flow measurements were conducted before exercise, and then every 10 min during each exercise bout. Ex: exercise; BF: breakfast; IM: intra-meal; CAT: catheterization.
cling with a 5-min pause. The intensity of the exercise was individually set as 50 % of the maximal workload (126 ± 13 w).
Either the BCAA drink (BCAA trial) or the placebo drink (placebo trial) was given at 10 min of the 1st exercise bout. Radial arterial and femoral venous blood samples were taken immediately before the 1st exercise bout and every 10 min during each exercise bout. The blood samples were centrifuged at 3000 rpm for 15 min at 4 8C to separate the plasma or serum. The plasma and serum samples were then frozen and stored at -80 8C until analysis. Immediately after the blood sample was taken, the exercise was interrupted momentarily to measure the femoral arterial blood flow at each sampling point. The blood flow was measured using a triplex ultrasound Doppler scanner with a transducer operating at 10 Hz (Logiq 9, General Electric, Fairfield, CT, USA) within 15 seconds, and the exercise was restarted immediately after the measurement. It was preliminarily confirmed that the decrease in the blood flow due to the interruption of exercise was not induced by a momentary interruption (less than 15 seconds). The heart rate was monitored throughout the experimental period.
Analysis
The plasma samples (200 μL) for amino acid determination were deproteinized with 200 μL of 3 % sulfosalicylic acid containing 400 μM S-(2-aminoethyl)-L-cysteine as an internal standard. The supernatant was assayed with an automatic amino acid analyzer (L-8500, Hitachi, Tokyo, Japan). The plasma glucose and free fatty acids (FFA) concentrations were measured by the spectrophotometric method using commercial kits (Determiner GL-E, Kyowa Medex, Tokyo, Japan and NEFA C-Test Wako, Wako Pure Chemical Industries, Osaka, Japan). The serum insulin level was measured with the commercial sandwich enzyme linked immunosorbent assay kit (LS Reagent Eiken Insulin kit, Eiken Chemical, Tokyo, Japan). The serum growth hormone (GH) level was measured with the commercial radioimmunoassay kit (GH kit Daiichi, Daiichi Radioisotope Laboratories, Tokyo, Japan).
Calculations
The net balances of amino acid, glucose and FFA were calculated as the product of the arteriovenous differences of plasma concentration and the blood flow. The net balance across the working leg was determined by the formula (A -F) × A f × (1 -Ht A ), where A is the arterial plasma concentration, F is the femoral venous plasma concentration, A f is the blood flow of femoral artery, and Ht A is the hematcrit of arterial blood. The cumulative net balance across the leg was calculated as the area under the net balance curve.
Statistical analysis
The results are expressed as means ± SEM. Comparisons between the means of two trials were performed by the paired Student's t-test. Comparisons between the basal level (0 min) and each time point during the exercise period within the trial were performed by Fisher's PLSD test after one-way ANOVA. The above analyses were performed using the Stat View version 5.0 software package (SAS, Inc., Cary, NC, USA). A level of p < 0.05 was used as the criterion for statistical significance, although p values of < 0.10 were also presented to indicate trends.
Results
Heart rate and blood flow
The heart rate and blood flow in the femoral artery significantly increased, 2 times and 8 times respectively, by moderate cycling exercise in both trials ( Table 1) . These parameters remained at higher levels during the exercise period, and they did not differ at any point between the BCAA and the placebo trial.
Plasma concentration and net balance of amino acids during exercise
The arterial plasma BCAA concentration did not change during the exercise period in the placebo trial. However, the plasma BCAA concentration in the BCAA trial significantly increased after the test drink ingestion, and thereafter remained at a higher level during the exercise period ( Table 2 ). In the placebo trial, the net BCAA balance across the working leg did not change by exercise, and no BCAA uptake into the working leg was observed during exercise. However, the BCAA ingestion induced the muscle BCAA uptake, and this BCAA uptake coincided with an increase in the plasma BCAA level ( Table 3 ). Significant differences in the cumulative net BCAA balance across the working leg were observed after test drink ingestion and during the 3rd exercise bout between the trials ( Table 4) .
The arterial plasma Phe concentration did not change during the exercise period in either trial, and no difference was observed between the trials ( Table 2 ). The net Phe balance across the working leg was negative during the experimental period, especially Nutrition during the 3rd exercise bout (Table 3) , and Phe release from the leg during exercise was significantly higher than the basal level in the placebo trial (exercise vs. basal: 0.97 ± 0.28 vs. 0.23 ± 0.22 μmol/min, p < 0.05). On the other hand, the Phe release did not increase after the test drink ingestion in the BCAA trial (Table 3) , and the cumulative Phe release from the working leg after the test drink ingestion in the BCAA trial tended to be lower than that in the placebo trial (Fig. 2 A) . In the BCAA trial, the Phe release decreased during the 3rd exercise bout, and the cumulative Phe release during 3rd exercise bout was significantly lower than that in the placebo trial (Fig. 2 B) .
The arterial plasma Arg concentration did not change during the exercise period in the placebo trial. While the arterial plasma Arg concentration significantly increased after the BCAA drink ingestion ( Table 2) . Arg was released from the leg during the exercise period in the placebo trial. In contrast, no Arg release was observed in the BCAA trial during the exercise ( Table 3) . A significant difference in the cumulative net Arg balance across the leg was observed after the test drink ingestion between the trials ( Table 4) . 
Nutrition
The arterial plasma Ala concentration significantly increased during exercise in both trials. The arterial plasma Gln concentration increased during exercise in both trials, but the change was only significant in the BCAA trial. There was no significant difference in the plasma Ala and Gln concentrations between the trials at each point ( Table 2 ). The net balance of Ala and Gln across the working leg did not change during exercise in both trials. The Ala release at 60 min tended to be lower in the BCAA trial than in the placebo trial (p < 0.1), and the Gln release from the leg at 60 min in the BCAA trial was significantly lower than that in the placebo trial (Table 3) . However, no significant difference in the cumulative net balance of Ala and Gln across the leg was observed after the test drink ingestion and during the 3rd exercise bout between the trials ( Table 4) .
Hormonal and metabolic response to exercise
The arterial serum insulin level significantly increased at 35 min, and then decreased in both trials. There was no significant difference in the serum insulin level between the trials at each point. The arterial serum GH level increased during the exercise, but the change was not significant in either trial. The serum GH level at 35 min in the BCAA trial was significantly higher than that in the placebo trial, but there was no other significant difference between the trials ( Table 5 ).
The arterial plasma glucose concentration significantly increased and peaked at 35 min, and then decreased to a level lower than the basal level during the 3rd exercise bout in the placebo trial. In the BCAA trial, the glucose concentration significantly increased after consuming the test drink, and thereafter it returned to basal level. The glucose concentration at 60 min in the 3rd exercise bout tended to be higher in the BCAA trial than that in the placebo trial (p < 0.1). The net glucose balance across the leg significantly increased during exercise in both trials. There was no significant difference in the net glucose balance between the trials at each point ( Table 5 ).
The arterial plasma FFA concentration significantly decreased until 60 min and then returned to the basal level at 70 min in both trials. The net FFA balance across the leg showed an uptake immediately after the start of exercise, and the FFA uptake then gradually increased during exercise in both trials. There was no difference in the plasma FFA concentration and the net FFA balance between the trials at each point ( Table 5) .
Discussion
The present study demonstrates that moderate exercise induced an increase in the Phe release from the working leg muscles, especially during the later exercise period, and a single intake of 2 g of BCAA with Arg supplementation was found to suppress such catabolic response during exercise in healthy untrained individuals.
Many researchers have reported an increase in proteolysis of whole-body protein and an increase in amino acid utilization as an energy source during exercise [5, 6, 10, 23] . Moreover, it has been reported that some amino acids, such as BCAA, were an important energy source for contracting skeletal muscles during endurance exercise [11] , and Leu oxidation increased with the increase in exercise intensity [2, 14] . It has therefore been suggested that severe exercise accelerates skeletal muscle proteolysis. However, it is unclear whether or not endurance exercise at moderate intensity generally performed by untrained subjects accelerates skeletal muscle proteolysis. Therefore, we investigated the effect of endurance exercise at a moderate intensity, 50% of workload max equivalent to the intensity of fast walking and jogging, on the protein metabolism.
Furthermore, multiple BCAA supplementation has been reported to suppress protein breakdown induced by severe exercise (ap- Values are means ± SEM. The positive value indicates the amino acid uptake by the leg, and the negative value indicates the release from the leg. * p < 0.05 vs. placebo trial by the Paired t-test proximately 5.6 g, 77 mg/kg body wt and approximately 24 g, 308 mg/kg body wt) [17, 18] and reduce muscle damage following prolonged endurance exercise (40 g, approximately 500 mg/ kg body wt) [4] . BCAA supplementation during exercise is thus suggested to effectively suppress proteolysis during exercise. However, the BCAA dosages investigated by previous studies are too high to be practically consumed by humans, and the minimum dosage to produce the beneficial effects of BCAA supplementation remains thus to be established. We recently investigated the minimal dose responsible for an increase in the blood BCAA level in a resting condition in healthy subjects. The peak plasma BCAA concentration was increased dose-dependently after BCAA ingestion, but the plasma BCAA concentration returned to the basal level within 1 hour when less than 1 g of BCAA was ingested. The plasma BCAA concentration maintained at a significantly higher level 2 hours after the ingestion when more than 2 g of BCAA were ingested [8] . We therefore investigated the effect of a single ingestion of 2 g of BCAA, the dosage was expected to maintain a higher plasma BCAA level during 1 hr of moderate intensity exercise. The dosage in the present study (approximately 28 mg/kg body wt) corresponded to one third of the smallest dosage of a previous study [17] . After 2 g of BCAA ingestion, plasma BCAA concentration significantly increased and remained at a higher level until the end of the 1-hr exercise period which was the same as for the sedentary condition. Moreover, the uptake of BCAA into the working leg was only observed in the BCAA trial. This result indicates that the ingested BCAA, even though the dosage was only 2 g, was transferred into the working muscle during moderate-intensity exercise. Therefore, it was expected that the 2 g of BCAA supply may be useful for reducing muscle proteolysis during exercise.
In the placebo trial, the increase in the Phe release from the working leg was observed during exercise, especially in the later exercise period. In contrast, the Phe release from the working leg during exercise was suppressed in the BCAA trial in comparison to the placebo trial. These results suggested that moderate endurance exercise corresponding to fast walking and jogging induced an increase in proteolysis during exercise, especially during the later period, and the BCAA drink effectively suppressed the proteolysis induced by such exercise. During exercise, not only glucose and FFA but also amino acids are used as an energy source in working skeletal muscles [5, 6, 23] . There was no difference in the exercise intensity and exercise time between the trials. The energy expenditure during the exercise period was thus clearly the same in both trials. No difference in the cumulative net balance of glucose, FFA, Ala and Gln across the working leg during exercise was observed between the trials. It was therefore thought that the utilization of glucose, FFA and amino acids including BCAA, as an energy source, were the same in both trials. In skeletal muscle, BCAA was supplied from the blood, intracellular free amino acid pool, or protein in the muscle by proteolysis. The BCAA uptake from the blood to the leg was observed during exercise in the BCAA trial, but the BCAA uptake was not observed in the placebo trial. BCAA was thus suggested to be supplied by proteolysis in the skeletal muscle as an energy source in the placebo trial. On the other hand, BCAA was exogenously supplied to the working muscle in the BCAA trial as an energy source. Therefore, BCAA does not have to be supplied endogenously. During the BCAA trial, this exogenous BCAA supply suppressed the increase in proteolysis normally observed during the exercise period. The increased plasma glucose concentration later decreased, and the decreased plasma FFA concentration thereafter increased during the 3rd exercise bout in both trials. FFA uptake into the leg gradually increased during exercise in both trials. The main energy source was thus considered to shift from glucose to FFA during the 3rd exercise period. Moreover, the Ala and Gln release from the working leg tended to increase during the 3rd exercise bout in the placebo trial. It has been reported that the amino group of BCAA was transaminated to Ala and Gln via Glu, and thereafter was transferred to the liver and gut [7, 19] . Therefore, the increase in Ala and Gln release from the working leg during the later exercise period may be reflected in the increase in BCAA catabolism in the muscle. It has been reported that exercise-induced increase in Leu oxidation is enhanced in a glycogen-depleted subject [15] , and that extent of Leu oxidation could be reduced by glucose supplementation during exercise [24] . Moreover we showed that prolonged exercise induced an increase in Leu release from the gut and an increase in Leu uptake into skeletal muscle, and glucose ingestion suppressed the increase in Leu release from the gut and the increase in Leu uptake into skeletal muscle in dogs [9] . These results suggest that reduced carbohydrate availability increases the protein oxidation. Furthermore, clofibric acid, which is well known as a hyperlipidemic drug that stimulates fatty acid oxidation, has also been reported to stimulate the BCAA catabolism [13, 21] . Moreover, the hypothesis of the activation of the BCKDH complex, which is a rate-limiting enzyme of BCAA catabolism, in association with an increased degree of fatty acid oxidation has also been proposed [25] . Therefore, proteolysis was thought to have dramatically accelerated during the 3rd exercise bout due to both a decrease in carbohydrate availability and an increase in fat oxidation.
The BCAA drink used in the present study contained not only BCAA but also Arg. The addition of Arg to the BCAA supplement is considered to induce an additional anabolic effect on the protein metabolism by an increase in GH and insulin [12] and an increase in blood flow [22] . An increase in the plasma Arg level and Arg uptake into the muscle was observed in the BCAA trial. However, no differences in the blood flow and the release of insulin and growth hormone between the BCAA and the placebo trials were observed except for the plasma GH level at 35 min. It therefore seems that the contribution of Arg to this suppressive effect of the BCAA drink on the exercise induced muscle proteolysis in the present study was only a slight one. The Arg dosage (500 mg) in the BCAA drink in the present study was dramatically smaller than that used in previous reports (30 g and 5.6 -12.6 g) [3, 22] . As a result, the Arg dosage in the present study was probably insufficient to induce an additional metabolic effect via increases in the blood flow, insulin levels or GH secretion.
In summary, this study demonstrated that endurance exercise at moderate intensity induces proteolysis. Furthermore, a single ingestion of 2 g of BCAA with Arg at the onset of exercise results in an increase in the BCAA circulatory level, the BCAA uptake into working leg during the exercise, and the suppression of Phe release from the leg during late exercise period. Overall, these results suggest that the 2 g of BCAA intake at the onset of exercise can effectively suppress skeletal muscle proteolysis induced by endurance exercise at a moderate intensity. However, further investigations are needed to clarify whether the addition of Arg to BCAA supplements enhances the suppressive effect on the protein metabolism.
